Abstract
The differential diagnosis of inflammatory myelopathies is broad. Autoimmune myelopathies represent a heterogeneous but significant portion of inflammatory myelopathies. The discovery of serologic biomarkers of autoimmune myelopathies (including aquaporin-4 and collapsin response-mediator protein-5 [CRMP-5] immunoglobulin [Ig]Gs) supports the concept of an autoimmune attack targeting the spinal cord. Neuroimaging, in particular MRI, may reveal distinctive patterns of signal abnormality suggesting an autoimmune etiology, such as longitudinally extensive transverse myelitis in neuromyelitis optica spectrumdisorders or tract-specific changes in paraneoplastic disorders. IgG biomarkers of autoimmune myelopathies enable more precise disease classification and have the potential to direct a cancer search, predict outcome, guide therapeutic decision making, and lead to future development of antigen-specific targeted therapies. The goal of initial immunotherapy is to reverse or halt progression. Long-term immunotherapy aims to maintain remission and prevent relapse.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 776-799 |
| Number of pages | 24 |
| Journal | CONTINUUM Lifelong Learning in Neurology |
| Volume | 17 |
| Issue number | 4 |
| State | Published - Aug 2011 |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
- Genetics(clinical)
Cite this
Autoimmune myelopathies. / Flanagan, Eoin; Lennon, Vanda A; Pittock, Sean J.
In: CONTINUUM Lifelong Learning in Neurology, Vol. 17, No. 4, 08.2011, p. 776-799.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Autoimmune myelopathies
AU - Flanagan, Eoin
AU - Lennon, Vanda A
AU - Pittock, Sean J
PY - 2011/8
Y1 - 2011/8
N2 - The differential diagnosis of inflammatory myelopathies is broad. Autoimmune myelopathies represent a heterogeneous but significant portion of inflammatory myelopathies. The discovery of serologic biomarkers of autoimmune myelopathies (including aquaporin-4 and collapsin response-mediator protein-5 [CRMP-5] immunoglobulin [Ig]Gs) supports the concept of an autoimmune attack targeting the spinal cord. Neuroimaging, in particular MRI, may reveal distinctive patterns of signal abnormality suggesting an autoimmune etiology, such as longitudinally extensive transverse myelitis in neuromyelitis optica spectrumdisorders or tract-specific changes in paraneoplastic disorders. IgG biomarkers of autoimmune myelopathies enable more precise disease classification and have the potential to direct a cancer search, predict outcome, guide therapeutic decision making, and lead to future development of antigen-specific targeted therapies. The goal of initial immunotherapy is to reverse or halt progression. Long-term immunotherapy aims to maintain remission and prevent relapse.
AB - The differential diagnosis of inflammatory myelopathies is broad. Autoimmune myelopathies represent a heterogeneous but significant portion of inflammatory myelopathies. The discovery of serologic biomarkers of autoimmune myelopathies (including aquaporin-4 and collapsin response-mediator protein-5 [CRMP-5] immunoglobulin [Ig]Gs) supports the concept of an autoimmune attack targeting the spinal cord. Neuroimaging, in particular MRI, may reveal distinctive patterns of signal abnormality suggesting an autoimmune etiology, such as longitudinally extensive transverse myelitis in neuromyelitis optica spectrumdisorders or tract-specific changes in paraneoplastic disorders. IgG biomarkers of autoimmune myelopathies enable more precise disease classification and have the potential to direct a cancer search, predict outcome, guide therapeutic decision making, and lead to future development of antigen-specific targeted therapies. The goal of initial immunotherapy is to reverse or halt progression. Long-term immunotherapy aims to maintain remission and prevent relapse.
UR - http://www.scopus.com/inward/record.url?scp=80053908445&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053908445&partnerID=8YFLogxK
M3 - Article
VL - 17
SP - 776
EP - 799
JO - Continuum (Minneapolis, Minn.)
JF - Continuum (Minneapolis, Minn.)
SN - 1080-2371
IS - 4
ER -